Research Roundup


Debbie Rigby takes a look at research news from around the world

Statin-associated Side Effects

Statins are associated with various statin-associated symptoms (SAS), including statin-associated muscle symptoms (SAMS), diabetes mellitus (DM), and central nervous system complaints. Clinically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune myopathy (SINAM), are rare.

J Am Coll Cardiol. 2016;67(20):2395-2410.

 

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation

A Danish nationwide observational cohort study of nearly 62,000 patients with non-valvular atrial fibrillation who were naïve to oral anticoagulants has concluded that all NOACs seem to be safe and effective alternatives to warfarin in a routine care setting. No significant difference was found between NOACs and warfarin for ischaemic stroke. The risks of death, any bleeding, or major bleeding were significantly lower for apixaban and dabigatran compared with warfarin.

BMJ 2016;353:i3189

 

Prioritizing interventions to address polypharmacy in Australian aged care facilities

This study prioritized a range of potential interventions that may be used to assist clinicians and policy makers develop a comprehensive strategy to manage polypharmacy in RACFs. The top interventions in rank order were ‘implementation of a pharmacist-led medication reconciliation service for new residents’, ‘conduct facility-level audits and feedback to staff and healthcare professionals’, ‘develop deprescribing scripts to assist clinician-resident discussion’, ‘develop or revise prescribing guidelines specific to older people with multimorbidity in RACFs’, ‘implement electronic medication charts and records’ and ‘better support Medication Advisory Committees (MACs) to address medication appropriateness’.

Research in Social and Administrative Pharmacy, Available online 15 June 2016

 

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin is associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.

New England Journal of Medicine, June 14, 2016

 

Previous Heinz taken to court over toddler foods
Next Pharmacists can have key role in antimicrobial stewardship

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.